|Videos|November 29, 2021
ESMO 2021 Updates in HER2+ Metastatic Gastric and Gastroesophageal Cancer
Key opinion leaders in gastric cancers comment on ESMO 2021 updates in metastatic HER2+ esophagogastric adenocarcinoma and metastatic HER2+ gastric or gastroesophageal junction cancer.
Advertisement
Data from the following clinical trials are discussed:
- LBA54 - Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2-positive locally advanced or metastatic esophagogastric adenocarcinoma (EGA): Results of the randomized phase 2 INTEGA trial (
INTEGA ) - LBA55 - Primary analysis of a phase 2 single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen (
DESTINY-Gastric02 )
Advertisement
Related to this article
Experts reveal their top picks for gastrointestinal oncology presentations from the 2026 ASCO Annual Meeting.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
Sonesitatug vedotin improved overall survival in pretreated CLDN18.2-positive advanced gastric/GEJ cancers in the phase 3 CLARITY-Gastric01 trial.
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
The FDA has approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
Advertisement
Advertisement
Trending on OncLive
1
FDA CTGTAC Votes in Favor of RP1/Nivolumab Data in Advanced Melanoma
2
FDA Grants Priority Review to Subcutaneous Amivantamab in Head and Neck Cancer
3
Precision Advances Have Transformed Lung Cancer Care, But Key Barriers Persist
4
FDA Awards Orphan Drug Designation to Enzomenib for ALL
5